RxDoctor Payments Data

Christopher Jones, MD

Transplant Surgery · Louisville, KYNPI 1598812315

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (37.1%), education and speaking fees — rather than concentrated in one kind of arrangement. Veloxis Pharmaceuticals, Inc. accounts for 79.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2020 at $13,664 and has fallen 95.8% since, to $579 in 2025.

$33,691in general payments, 2019–2025

Across 107 payments — averaging $314.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Veloxis Pharmaceuticals, Inc.$27K
  • Intuitive Surgical$4K
  • Stryker$1K
  • Medtronic$230
  • Novartis$219
  • Paragonix Technologies, Inc.$170
  • plus $1K from 13 others
$12,027in research payments, 2019–2025

Across 1 payment — averaging $12,027 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$12K

What the payments were for

  • Consulting fees$12,50037%
  • Speaking & faculty fees$4,74014%
  • Travel & lodging$4,07412%
  • Food & beverage$4,37713%
  • Education$8,00024%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant surgery providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$8,426
Medicare patients
27
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Valganciclovir Hcl25$8,931
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim46$268
Prednisone39$110
Ondansetron Hcl12$102
Carvedilol11$80
Amlodipine Besylate15$63

Paid to pharmacies, not to this prescriber.

Other transplant surgery in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →